A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX

SIMPLE SUMMARY: Neoadjuvant chemoradiotherapy followed by surgery is currently standard of care in esophageal adenocarcinoma. However, prognosis remains dismal. The aim of our study was to assess the feasibility of administering six cycles of adjuvant S-1 and oxaliplatin following neoadjuvant chemor...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Stroes, Charlotte I., Schokker, Sandor, Molenaar, Remco J., Mathôt, Ron A. A., Bijlsma, Maarten F., van der Woude, Stephanie O., Belo Pereira, João P., Hooijer, Gerrit K. J., Verhoeven, Rob H. A., Cats, Annemieke, Grootscholten, Cecile, van Sandick, Johanna W., Creemers, Geert-Jan, Nieuwenhuijzen, Grard A. P., Haj Mohammad, Nadia, Ruurda, Jelle P., Meijer, Sybren L., Hulshof, Maarten C. C. M., van Berge Henegouwen, Mark I., van Laarhoven, Hanneke W. M.
Format: Artigo
Langue:Inglês
Publié: MDPI 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7922275/
https://ncbi.nlm.nih.gov/pubmed/33671266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13040839
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires